Shots:

• The company reported the positive findings of a pooled analysis of six ongoing clinical studies which includes P-IIb/IIIb LATTE-2- ATLAS- ATLAS-2M- FLAIR- POLAR- and CUSTOMIZE studies evaluating long-acting cabotegravir and rilpivirine regimen in 1-744 patients with HIV-1 infection across 16 countries
• The positive findings showed 93% of participants maintained their injection visits amid the COVID-19 with no instances of virologic failure or development of resistance and showed good tolerability
• Long-acting regimen of cabotegravir and rilpivirine is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA <50 copies/mL) and has received Health Canada’s approval in Mar’2020

 ­ Ref: ViiV Healthcare | Image: Fierce Pharma